Cornerstone Investment Partners LLC Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Cornerstone Investment Partners LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.7% during the 4th quarter, Holdings Channel reports. The fund owned 1,940 shares of the medical research company’s stock after purchasing an additional 69 shares during the period. Cornerstone Investment Partners LLC’s holdings in Charles River Laboratories International were worth $358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International during the third quarter worth $59,000. Finally, ORG Wealth Partners LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $163.62 on Tuesday. The firm has a 50-day simple moving average of $170.50 and a 200-day simple moving average of $186.58. The stock has a market capitalization of $8.37 billion, a price-to-earnings ratio of 1,090.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.46 earnings per share. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CRL shares. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Finally, TD Cowen upped their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).